Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Children Asthma Therapy Optimal (CATO)
NCT00158834Phase 3Completed
- Sponsor
- GSK
- Start
- Nov 1999
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of salmeterol + fluticasone in asthma (2 arms), sponsored by GSK. Primary endpoint: Asthma symptom free days at 12 weeks. Started Nov 1999; status: completed.
02
Drugs
salmeterol + fluticasone
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00158834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00158834.